Navigation Links
Kendle Names Jarrod Pontius Chief Legal Officer

CINCINNATI, June 29 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of Jarrod Pontius to the position of Chief Legal Officer. In this role, Pontius will provide global leadership for all legal services, corporate governance and general corporate legal matters for Kendle. Pontius will be based in Kendle's global headquarters in Cincinnati and will report to Chairman and Chief Executive Officer, Candace Kendle, PharmD. He will serve on the Company's Executive Committee.

(Logo: )

"I am pleased to welcome Jarrod back to Kendle," said Dr. Kendle. "He brings a broad base of legal expertise as well as Kendle experience and we are happy to have a professional of his caliber to lead our global legal team. Jarrod has been instrumental in a number of our recent acquisitions and will be key to the future growth of Kendle."

Pontius brings more than a decade of experience in both the legal and corporate legal environments to Kendle. He has a demonstrated track record of success in the areas of corporate law, mergers and acquisitions, corporate development, public company reporting and securities compliance, corporate financing activities and corporate governance. He rejoins Kendle, from General Cable Corporation, a Fortune 500 publicly traded supplier of wire and cable products, where he had served as Assistant General Counsel since 2007. Previously Pontius was Corporate Counsel and Senior Corporate Counsel from 2002 through 2007 for Kendle. His experience also includes serving as an Associate in the business/corporate department of the Cincinnati law firm Frost Brown Todd LLC.

Pontius is a member of both the Cincinnati and Ohio Bar Associations and the Association of Corporate Counsel and is a graduate of the Cincinnati Academy of Leadership for Lawyers. He received his Juris Doctorate from Case Western Reserve University in Cleveland and holds a Bachelor of Science in finance from Indiana University.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at

SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
2. Kendle Announces First Quarter 2009 Results
3. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
4. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
5. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
6. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
7. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
8. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
9. Kendle to Present at the 2008 Credit Suisse Health Care Conference
10. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
11. Kendle Named a Best Place to Work in Greater Cincinnati
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced today ... independent director, and the Company welcomes Neil Woodford,s ... a recent anonymous internet report on NW Bio.  The ... Linda Powers stated, "We agree with Mr. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
Breaking Biology News(10 mins):